If the ongoing and/or future phase 3 studies confirm the early-phase trial results reported here, HER2-targeting ADCs may provide a future novel treatment option for advanced “HER2-low” breast cancer (including TNBC) patients. The gene discussed is ERBB2; the disease is breast cancer.